Updated Jul 27, 7:36 PM · 60 sources analyzed
Key Takeaways
Genfit's UNVEIL-IT Phase 2 for VS-01 in liver failure was terminated with no results disclosed, narrowing an already thin pipeline.
NuCana's NUC-3373 combination study in solid tumors was terminated, compounding platform-level uncertainty for NCNA shareholders.
Amgen's rocatinlimab and sotorasib Phase 3 programs completed registry enrollment — data packages and filing timelines are the next catalysts.
🏆 Winner
Amgen — multiple Phase 3 programs across rocatinlimab and sotorasib reached completion milestones, signaling data packages are being assembled for potential regulatory submissions.
📉 Loser
Genfit — the UNVEIL-IT Phase 2 termination removes a clinical asset without explanation, leaving investors with no clarity on whether the VS-01 program has a future.
🔭 Watch Next
Amgen's CodeBreaK 300 (sotorasib + panitumumab in KRAS G12C CRC) and ROCKET rocatinlimab Phase 3 data presentations are the most consequential near-term readouts visible from today's sources, with ESMO and EADV 2026 as likely venues.
MapLight Therapeutics files material 8-K disclosing new development
MapLight Therapeutics (watchlist: MPLT) filed an 8-K with the SEC on July 27 disclosing Items 7.01, 8.01, and 9.01 — a combination that typically signals a press release of material corporate news rather than routine governance. The specific content of the disclosure has not been detailed in the available source text, but Item 8.01 ('Other Events') filings of this type often accompany clinical updates, partnership announcements, or business developments. Biotech professionals tracking MPLT should pull the full filing directly for context, as the filing structure suggests a potentially material development beyond administrative housekeeping.
SEC EDGAR ↗Amgen
Rocatinlimab in Moderate-to-severe atopic dermatitis (adolescents)
The ROCKET-VOYAGER and ROCKET-IGNITE Phase 3 studies, as well as the adolescent safety/tolerability study (NCT05633355), are all now marked as Completed on ClinicalTrials.gov. No efficacy or safety results have been released in the available source text; full data have not yet been disclosed publicly from these registry entries.
Why it matters
Rocatinlimab's Phase 3 program completing across three studies simultaneously suggests Amgen is consolidating a data package. The competitive pressure in atopic dermatitis is intense, and Amgen will need to show durable response and a differentiated safety profile — particularly around vaccine interference (the VOYAGER sub-study) — to carve out meaningful market share.
What to watch
Watch for Amgen to present full ROCKET Phase 3 data at a major dermatology congress such as EADV (expected late 2026) and any subsequent BLA filing announcement.
Amgen
Sotorasib + Panitumumab in KRAS G12C-mutated colorectal cancer (previously treated)
The CodeBreaK 300 Phase 3 trial (NCT05198934) comparing sotorasib 240 mg plus panitumumab versus investigator's choice in previously treated KRAS G12C-mutant CRC is now marked Completed on ClinicalTrials.gov. No progression-free survival (PFS) results or additional outcome data are available from this registry update alone.
Why it matters
The trial completion marker tells us the data lock is either imminent or done — what matters next is whether the PFS benefit is large enough to justify a label in a heavily pre-treated CRC population where the unmet need is high but the bar for differentiation versus chemotherapy is meaningful. Investors should track the sNDA filing timeline carefully.
What to watch
Watch for Amgen to disclose full CodeBreaK 300 OS and PFS data at ESMO 2026 (September) and any supplemental NDA submission announcement.
Akero Therapeutics
Efruxifermin (EFX) in Compensated cirrhosis due to NASH (F4 fibrosis)
The Symmetry Phase 2 trial (NCT05039450) of efruxifermin in biopsy-proven F4 compensated NASH cirrhosis is now marked Completed on ClinicalTrials.gov. No histological response rates, fibrosis improvement rates, or safety data are provided in this registry update.
Why it matters
Akero's F4 cirrhosis program is strategically important because resmetirom is approved only through F2-F3 fibrosis — a successful readout in cirrhosis would open a differentiated label. The absence of results from this registry update keeps the investment thesis in a holding pattern until data are disclosed.
What to watch
Watch for Akero to present Symmetry efficacy and histology data at AASLD The Liver Meeting (expected November 2026) and any Phase 3 cirrhosis program announcement.
Genfit
VS-01 in Acute-on-chronic liver failure (ACLF) with ascites
The UNVEIL-IT Phase 2 trial (NCT05900050) evaluating VS-01, an intraperitoneal liposomal formulation, in patients with ACLF and ascites has been marked Terminated on ClinicalTrials.gov. No efficacy results, safety signal descriptions, or reason for termination are provided in the registry entry.
Why it matters
A terminated Phase 2 in ACLF — a high-mortality condition with no approved pharmacotherapy — is a setback for Genfit's attempt to diversify its liver disease portfolio beyond its NAS/fibrosis franchise. Without a disclosed reason, it is unclear whether this reflects safety, futility, or operational factors, but any of these would concern investors evaluating pipeline risk.
What to watch
Watch for Genfit to issue a formal statement on the UNVEIL-IT termination rationale and whether any VS-01 development continues in an alternative indication or formulation.
The ROCKET-VOYAGER and ROCKET-IGNITE Phase 3 studies, as well as the adolescent safety/tolerability study (NCT05633355), are all now marked as Completed on ClinicalTrials.gov. No efficacy or safety results have been released in the available source text; full data have not yet been disclosed publicly from these registry entries.
Why it matters
Completion of multiple Phase 3 rocatinlimab studies across adult and adolescent populations sets up a potential regulatory filing that would pit the anti-OX40 mechanism directly against approved IL-4/IL-13 blockers such as dupilumab and lebrikizumab.
Analysis
Rocatinlimab's Phase 3 program completing across three studies simultaneously suggests Amgen is consolidating a data package. The competitive pressure in atopic dermatitis is intense, and Amgen will need to show durable response and a differentiated safety profile — particularly around vaccine interference (the VOYAGER sub-study) — to carve out meaningful market share.
What to watch
Watch for Amgen to present full ROCKET Phase 3 data at a major dermatology congress such as EADV (expected late 2026) and any subsequent BLA filing announcement.
The CodeBreaK 300 Phase 3 trial (NCT05198934) comparing sotorasib 240 mg plus panitumumab versus investigator's choice in previously treated KRAS G12C-mutant CRC is now marked Completed on ClinicalTrials.gov. No progression-free survival (PFS) results or additional outcome data are available from this registry update alone.
Why it matters
KRAS G12C-targeted therapy in colorectal cancer remains a contested space; completion of this registrational trial is a prerequisite for any sNDA submission and positions Amgen ahead of next-generation KRAS inhibitors from Revolution Medicines and others.
Analysis
The trial completion marker tells us the data lock is either imminent or done — what matters next is whether the PFS benefit is large enough to justify a label in a heavily pre-treated CRC population where the unmet need is high but the bar for differentiation versus chemotherapy is meaningful. Investors should track the sNDA filing timeline carefully.
What to watch
Watch for Amgen to disclose full CodeBreaK 300 OS and PFS data at ESMO 2026 (September) and any supplemental NDA submission announcement.
The Symmetry Phase 2 trial (NCT05039450) of efruxifermin in biopsy-proven F4 compensated NASH cirrhosis is now marked Completed on ClinicalTrials.gov. No histological response rates, fibrosis improvement rates, or safety data are provided in this registry update.
Why it matters
Completion of Symmetry is a key gating event for Akero's NASH cirrhosis program; the results will inform whether efruxifermin can compete in the highest-severity NASH segment against Madrigal's resmetirom and emerging combination regimens.
Analysis
Akero's F4 cirrhosis program is strategically important because resmetirom is approved only through F2-F3 fibrosis — a successful readout in cirrhosis would open a differentiated label. The absence of results from this registry update keeps the investment thesis in a holding pattern until data are disclosed.
What to watch
Watch for Akero to present Symmetry efficacy and histology data at AASLD The Liver Meeting (expected November 2026) and any Phase 3 cirrhosis program announcement.
The UNVEIL-IT Phase 2 trial (NCT05900050) evaluating VS-01, an intraperitoneal liposomal formulation, in patients with ACLF and ascites has been marked Terminated on ClinicalTrials.gov. No efficacy results, safety signal descriptions, or reason for termination are provided in the registry entry.
Why it matters
Termination of UNVEIL-IT removes one of Genfit's clinical-stage assets and narrows its pipeline at a time when the company has been working to rebuild following earlier NASH setbacks.
Analysis
A terminated Phase 2 in ACLF — a high-mortality condition with no approved pharmacotherapy — is a setback for Genfit's attempt to diversify its liver disease portfolio beyond its NAS/fibrosis franchise. Without a disclosed reason, it is unclear whether this reflects safety, futility, or operational factors, but any of these would concern investors evaluating pipeline risk.
What to watch
Watch for Genfit to issue a formal statement on the UNVEIL-IT termination rationale and whether any VS-01 development continues in an alternative indication or formulation.
The modular, multi-arm Phase 1/2 study of NUC-3373 (a fluorouracil prodrug) in combination with other agents in advanced solid tumors (NCT05714553) has been marked Terminated on ClinicalTrials.gov. No efficacy data, response rates, or reason for termination are disclosed in the registry entry.
Why it matters
NUC-3373 was NuCana's follow-on to its earlier nucleotide prodrug programs; termination of this combination study leaves the company with a narrowed clinical footprint and raises questions about the ProTide platform's ability to deliver differentiated outcomes in solid tumors.
Analysis
NuCana has faced repeated clinical headwinds with its nucleotide prodrug platform, and this termination compounds uncertainty for NCNA investors. Without a disclosed reason, the market will likely assume the worst — either futility or tolerability concerns in the combination setting — until the company provides clarification.
What to watch
Watch for NuCana to provide a public explanation of the NUC-3373 termination and whether any remaining pipeline programs — including NUC-7738 — continue with active enrollment.
Boehringer Ingelheim's BI 1819479 completes Phase 2 in idiopathic pulmonary fibrosis
A Phase 2 study of BI 1819479 in adults with idiopathic pulmonary fibrosis (IPF) — a progressive, fatal scarring of the lung — has completed enrollment and study procedures, as reflected in a ClinicalTrials.gov status update to Completed.
Why it matters
IPF remains an area of high unmet need despite the availability of pirfenidone and nintedanib; novel mechanisms that slow or reverse fibrosis progression are actively sought, and BI 1819479's Phase 2 completion sets up a potential data readout that could validate or invalidate its target pathway.
Analysis
Boehringer Ingelheim has sustained investment in IPF beyond nintedanib, and a Phase 2 signal from BI 1819479 could support a Phase 3 program in a market where no new mechanistic class has been approved in over a decade. The IPF competitive landscape is heating up with multiple assets in mid-to-late development, making the timing and strength of any efficacy signal here commercially meaningful.
What to watch
Watch for Boehringer Ingelheim to present BI 1819479 Phase 2 lung function and safety data at a respiratory congress such as ERS 2026 (September) or ATS 2027.
Siltuximab for CAR-T toxicity management completes Phase 2 evaluation at UAB
A Phase 2 study evaluating siltuximab — an IL-6 inhibitor (a drug that blocks the inflammatory signaling protein IL-6) — to reduce the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) in CAR-T cell therapy recipients has completed at the University of Alabama at Birmingham.
Why it matters
As CAR-T therapies expand across hematologic and solid tumor indications, optimizing toxicity management protocols is a critical bottleneck; data from this study could inform whether IL-6 blockade with siltuximab offers advantages over the current standard of tocilizumab in the CAR-T supportive care setting.
Analysis
Toxicity management is an underappreciated commercial differentiator in the CAR-T space — companies that can demonstrate cleaner safety profiles or superior supportive care protocols gain a real-world adoption edge. Results from this study, if favorable for siltuximab, could shift institutional protocols and create a product opportunity for EUSA Pharma (now part of Jazz Pharmaceuticals) in the CAR-T support market.
What to watch
Watch for publication of the siltuximab CAR-T toxicity data in a peer-reviewed hematology or oncology journal, and whether any CAR-T developers incorporate siltuximab into their institutional management guidelines.
Janssen's guselkumab plus golimumab dual-cytokine blockade Phase 2 in psoriatic arthritis completes
A Phase 2 study (NCT05071664) evaluating the combination of guselkumab (an IL-23 inhibitor) and golimumab (a TNF inhibitor) in psoriatic arthritis (PsA) patients with inadequate response to prior anti-TNF therapy has been marked Completed on ClinicalTrials.gov.
Why it matters
Dual cytokine blockade combining IL-23 and TNF pathways is a mechanistically novel approach in PsA — if the combination shows superior joint and skin clearance without additive toxicity, it could challenge the current sequential monotherapy paradigm and reshape treatment algorithms in inflammatory arthritis.
Analysis
Janssen's willingness to test combination biologic therapy in PsA reflects competitive pressure from IL-17 inhibitors and oral JAK inhibitors that have taken share in this indication. A positive Phase 2 signal could justify a Phase 3 program for a combination that would be uniquely positioned — though payer acceptance of two-biologic regimens remains an open commercial challenge.
What to watch
Watch for Janssen to disclose guselkumab plus golimumab efficacy and safety results from this Phase 2 at EULAR 2027 or in a peer-reviewed rheumatology journal, and whether a Phase 3 combination program is announced.
MapLight Therapeutics
MapLight Therapeutics filed an 8-K (Items 7.01, 8.01, 9.01) with the SEC on July 27, 2026, signaling a material corporate disclosure beyond routine governance.
Why it matters
Item 8.01 ('Other Events') combined with 7.01 and 9.01 typically accompanies press releases disclosing clinical updates, partnerships, or business developments — making this filing potentially relevant for anyone tracking the MPLT pipeline.
Analysis
MapLight is a CNS-focused biotech developing drugs for psychiatric conditions including schizophrenia; any material disclosure from a company at this stage of development warrants direct review of the filed exhibit. The filing structure suggests this is not routine administrative activity, though the exact content cannot be confirmed from available sources.
What to watch
Review the full 8-K exhibit filed with SEC EDGAR to identify the specific disclosure; watch for any accompanying press release from MapLight Therapeutics clarifying the nature of the event.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
MapLight Therapeutics filed an 8-K with the SEC disclosing Items 7.01, 8.01, and 9.01 on July 27, 2026. The filing structure — particularly Item 8.01 — typically indicates a material corporate or clinical disclosure; full content requires direct review of the EDGAR filing.
SEC EDGAR ↗